CD10, scored as positive versus negative all path 1 path 2 path 3 path 4 path 5 path 6 path 7 path 8 path 9 CD10 can be reproducibly scored, but is very.

Slides:



Advertisements
Similar presentations
Quantitative Assessment of Tissue-based IHC Biomarkers
Advertisements

Regulation of Consumer Tests in California AAAS Meeting June 1-2, 2009 Beatrice OKeefe Acting Chief, Laboratory Field Services California Department of.
TOP2A IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN UNSELECTED BREAST CANCER Amit Pancholi Molecular Profiling of Breast Cancer: Predictive Markers of Long.
Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 9 – Correlation and linear regression Marshall University.
Most Random Gene Expression Signatures are Significantly Associated with Breast Cancer Outcome Venet, et al. PLoS Computational Biology, 2011 Molly Carroll.
MYC/BCL2 protein coexpression contributes inferior outcome in DLBCL
Transforming Correlative Science to Predictive Personalized Medicine Richard Simon, D.Sc. National Cancer Institute
Statistical Issues in Incorporating and Testing Biomarkers in Phase III Clinical Trials FDA/Industry Workshop; September 29, 2006 Daniel Sargent, PhD Sumithra.
Clinical Trial Designs for the Evaluation of Prognostic & Predictive Classifiers Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer.
Sino-Danish Breast Cancer Research Centre Beijing Genomic Institute, Shenzhen University of Copenhagen University of Århus University of Southern Denmark.
HISTOLOGICAL QUALITY CONTROL OF FROZEN SAMPLES USING MATCHING FFPE TISSUE – PRELIMINARY RESULTS OF OUR INSTITUTIONAL BIOBANK E. Mattioli, E. Foglia Manzillo,
Richard Simon, D.Sc. Chief, Biometric Research Branch
Genomic signatures to guide the use of chemotherapeutics Authors: Anil Potti et. al Presenter: Jong Cheol Jeong.
Molecular Testing of lung cancer in routine practice
Genetic Regulators of Large-scale Transcriptional Signatures in Cancer Presented by Mei Liu September 26, 2007.
Re-Examination of the Design of Early Clinical Trials for Molecularly Targeted Drugs Richard Simon, D.Sc. National Cancer Institute linus.nci.nih.gov/brb.
Predictors of HER2 FISH amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis Maria Vittoria Dieci 1,
MammaPrint, the story of the 70-gene profile
Thoughts on Biomarker Discovery and Validation Karla Ballman, Ph.D. Division of Biostatistics October 29, 2007.
Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer (NCCTG N9831/BCIRG006/BCIRG005) 1 Concordance of HER2 Central Assessment.
Diagnostic Assays to Plan Specific Drug Treatment Elizabeth Hammond MD.
IN THE NAME OF GOD By: Dr malek. References Am J Clin Pathol. 2008;130(5): © 2008 American Society for Clinical Pathology Bryant J, Picot J,
Taiwan 2000 PETACC 3 ASCO 2009 Molecular markers in colon cancer have a stage specific prognostic value. Results of the translational study on the PETACC.
The 70 gene Mammaprint ™ signature: a comparison with traditional clinico-pathological parameters. Patrizia Querzoli 1, Massimo Pedriali 1, Gardenia Munerato.
A 14-gene prognosis signature predicts metastasis risk in node-negative, estrogen receptor-positive, Tamoxifen-treated breast cancer in different ethnogeographic.
Chapter 7 Essential Concepts in Molecular Pathology Companion site for Molecular Pathology Author: William B. Coleman and Gregory J. Tsongalis.
Enabling biomarker validation in breast cancer molecular subtypes: sensitivity and specificity of array-based subtype classification in 983 patients Balázs.
Sgroi DC et al. Proc SABCS 2012;Abstract S1-9.
A Quantitative Multi-Gene RT-PCR Assay for Prediction of Recurrence in Stage II Colon Cancer (CC): Selection of the Genes in 4 Large Studies and Results.
Pfetin, as a Prognostic Biomarker of Gastrointestinal Stromal Tumors Revealed by Proteomics Yoshiyuki Suehara 1 3 4, Kunihiko Seki 2, Kiyonaga Fujii 1,
BIOMARKERS Diagnostics and Prognostics. OMICS Molecular Diagnostics: Promises and Possibilities, p. 12 and 26.
Selection of Patient Samples and Genes for Disease Prognosis Limsoon Wong Institute for Infocomm Research Joint work with Jinyan Li & Huiqing Liu.
Michael Birrer Ian McNeish New Developments in Biology and Targets of Epithelial Ovarian Cancer.
INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,
An International Ki67 Reproducibility Study Nielsen TO et al. Proc SABCS 2012;Abstract S4-6.
The Use of Predictive Biomarkers in Clinical Trial Design Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute
Validation of four gene-expression risk scores in a large colon cancer cohort and contribution to an improved prognostic method Antonio F. Di Narzo 1,
Using Predictive Classifiers in the Design of Phase III Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute.
Poster Title ABSTRACT #59 Cell cycle progression genes differentiate indolent from aggressive prostate cancer. Steven Stone 1 Jack Cuzick 2, Julia Reid.
Tumor clock protein PER2 as a determinant of survival in patients (pts) receiving oxaliplatin-5-FU- leucovorin as 1st line chemotherapy for metastatic.
DEBIRI TACE Patterns and Predictors of Response
Prognostic and Predictive Factors: Current Evidence for Individualized Therapy Predictive Molecular Markers: Hormone Receptor Status Presented by Kathleen.
Introduction to Design of Genomic Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute
Scott Kopetz, MD, PhD Department of Gastrointestinal Medical Oncology
Annals of Oncology 23: 298–304, 2012 종양혈액내과 R4 김태영 / prof. 김시영.
Chips? SNPs? or PCR? What do we really want and what do we need? Heinz-Josef Lenz, MD Professor of Medicine Co-Director, Colorectal Center Co-Director,
G Mustacchi 1, F Zanconati 2, D Bonifacio 2, L Morandi 3, MP Sormani 4, A. Gennari 5, P Bruzzi 4 1: Centro Oncolgico University of Trieste 2: Inst of Pathology,
Validation and Interpretation in Cellular Pathology
miRNA-targets cross-talks: key players in glioblastoma multiforme
MicroRNA-34a: a key regulator in the hallmarks of renal cell carcinoma
Wijendra Senarathne1, Peggy Gates1, Semir Vranic2, Zoran Gatalica1
IOV – Istituto Oncologico Veneto I.R.C.C.S.
EMT inducing transcription factor SIP1: a predictive biomarker of colorectal cancer survival and recurrence? A Patel, R Sreekumar, R Bhome, KA Moutasim,
Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors  Jeffrey M. Conroy, Sarabjot Pabla, Sean T. Glenn,
A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients by Andrew J. Gentles, Ash A. Alizadeh,
Immunoguided Laser Assisted Microdissection Techniques for DNA Methylation Analysis of Archival Tissue Specimens  Franziska C. Eberle, Jeffrey C. Hanson,
Focus on lymphomas Cancer Cell
Jonathan W. Friedberg M.D., M.M.Sc.
Learning More from Microarrays: Insights from Modules and Networks
QuantiGene Plex Represents a Promising Diagnostic Tool for Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma  John S. Hall, Suzanne Usher, Richard.
Accurate Classification of Germinal Center B-Cell–Like/Activated B-Cell–Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase–Multiplex.
Recurrence-Associated Long Non-coding RNA Signature for Determining the Risk of Recurrence in Patients with Colon Cancer  Meng Zhou, Long Hu, Zicheng.
Validation of a Gene Expression Test for Mesothelioma Prognosis in Formalin-Fixed Paraffin-Embedded Tissues  Assunta De Rienzo, Robert W. Cook, Jeff Wilkinson,
Molecular prognostication of liver cancer: End of the beginning
SIRT1 is downregulated in human gastric cancer (GC).
FILM immunohistochemical protein signature is significantly associated with poor survival. FILM immunohistochemical protein signature is significantly.
Mir-128 reduction in breast cancer tissues correlates chemotherapy resistance and poor patient survival. Mir-128 reduction in breast cancer tissues correlates.
Reduced klotho expression in pancreatic cancer.
Defining the eTME genes.
Hege G. Russnes, et al: Breast Cancer Molecular Stratification From Intrinsic Subtypes to Integrative Clusters. The American Journal of Pathology. Vol.
Presentation transcript:

CD10, scored as positive versus negative all path 1 path 2 path 3 path 4 path 5 path 6 path 7 path 8 path 9 CD10 can be reproducibly scored, but is very sensitive to laboratory variations inducing variation of non-scored cases substantial fair very good substantial

CD10 same core, distinct staining differences sparse internal controls granulocyte stromal fibroblasts

less sensitive technique more sensitive technique strong staining / artifacts BCL-6

GCB versus non-GCB on the basis of CD10, MUM-1 and bcl-6 (25% cut-off levels) substantial fair substantial 0.72 moderate/fair moderate 0.42

Conclusions (LLBC, de Jong et al., JCO 2007) Using immunohistochemistry, prognostic biomarkers for DLBCL can be assessed with varying reliability Results in almost all markers are strongly influenced by technical variations (MUM-1, Ki-67, bcl-6) Immunohistochemical amplification techniques may result in unexpected variations (CD5, bcl-6) Results can be reliably interpreted when optimized stains are used and with well-defined scoring guidelines (kappa= ), including definitions of internal controls at this stage, risk-stratified treatment of DLBCL should be performed in clinical trials with central pathology review

Molecular quantitative techniques applicable to paraffin embedded tissue specimens Gene expression analysis in MCL using qRT-PCR

The proliferation signature: A gene-expression based predictor of survival in MCL (Cancer Cell 2003) Definition of prognostic subgroups in MCL Gene expression Profiling in MCL using Microarrays

Measurement of Proliferation using Ki-67 immunohistochemistry Low ProliferationHigh Proliferation

Survival according to Ki-67 Index (European MCL Study)

Prediction of survival in 73 fresh frozen MCL specimens according to a 5-gene-predictor

Statistical Analysis Application of Cox models and selection of the best 8 genes by stepwise methods, adjusted by bootstrap for a predictor of 5 genes Best model: RAN + MYC - TNFRSF10B + POLE2 + SLC29A2

Application of the 5-Gene-Predictor to Routine Diagnosis Validation of the modified assays in 13 samples with matched frozen and FFPE tissue available (Pearson correlation=0.77, p=0.002) Validation of the 5-Gene-predictor in an independent series of 23 MCL FFPE specimens

Prediction of survival in FFPE MCL specimen according to the 5-Gene-Predictor Rosenwald, Campo, et al., unpublished